François-Xavier Mahon

Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

David Marín, Alexandra Bazeos, François-Xavier Mahon et al. · Journal of Clinical Oncology · 2010 · 901 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure

Timothy P. Hughes, Michael J. Mauro, Jörge E. Cortes et al. · New England Journal of Medicine · 2019 · 467 citations · Full text

Medicine, Oncology, Pharmacology +9

BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia

Matthew S. Zabriskie, Christopher A. Eide, Srinivas K. Tantravahi et al. · Cancer Cell · 2014 · 366 citations · Full text

Medicine, Molecular Biology, Oncology +7

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

Philipp le Coutre, Oliver G. Ottmann, Francis J. Giles et al. · Blood · 2007 · 291 citations · Full text

Medicine, Oncology, Pharmacology +4

Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase

François-Xavier Mahon, Carla Boquimpani, Dong‐Wook Kim et al. · Annals of Internal Medicine · 2018 · 132 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11